MCID: NLL002
MIFTS: 26

Null Syndrome

Categories: Neuronal diseases, Eye diseases, Rare diseases

Aliases & Classifications for Null Syndrome

MalaCards integrated aliases for Null Syndrome:

Name: Null Syndrome 56
Pelizaeus-Merzbacher Disease, Null Syndrome 56
Plp1 Null Syndrome 56

Characteristics:

Orphanet epidemiological data:

56
null syndrome
Inheritance: X-linked recessive; Age of onset: Childhood; Age of death: adult;

Classifications:



External Ids:

Orphanet 56 ORPHA280234
ICD10 via Orphanet 34 E75.2

Summaries for Null Syndrome

MalaCards based summary : Null Syndrome, also known as pelizaeus-merzbacher disease, null syndrome, is related to rh deficiency syndrome and spastic paraplegia 2, x-linked. An important gene associated with Null Syndrome is PLP1 (Proteolipid Protein 1). The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and lung.

Related Diseases for Null Syndrome

Diseases related to Null Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 rh deficiency syndrome 11.4
2 spastic paraplegia 2, x-linked 10.8
3 anemia, hemolytic, rh-null, regulator type 10.8
4 symptomatic form of coffin-lowry syndrome in female carriers 9.5 PLP1 RHAG

Symptoms & Phenotypes for Null Syndrome

Drugs & Therapeutics for Null Syndrome

Drugs for Null Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1614)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9005-49-6 772 46507594
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-41-2 439260
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
5
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
6
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
8
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 1 122320-73-4 77999
9
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
10
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 111025-46-8 4829
11
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
12
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
13
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 57-83-0 5994
14
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
15
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
17
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
18
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
19
Cisplatin Approved Phase 4,Phase 2,Phase 1 15663-27-1 84093 441203 2767
20
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
21
Idarubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 58957-92-9 42890
22
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
23
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
24
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
25
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
26
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
27
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
28
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
29
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
30
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2 59467-70-8 4192
31
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
32
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
33
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 54-31-9 3440
34
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
35
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
36
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
37
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
38
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
39
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
40
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
41
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
42
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
43
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 9004-61-9 53477741 24759
44
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
45
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1 114798-26-4 3961
46
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
47
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
48
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
49
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
50
Amlodipine Approved Phase 4,Phase 2 88150-42-9 2162

Interventional clinical trials:

(show top 50) (show all 8220)

id Name Status NCT ID Phase Drugs
1 CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS Unknown status NCT00933400 Phase 4
2 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
3 Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
4 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
5 A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome Unknown status NCT02013102 Phase 4 Decitabine Injection
6 Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
7 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
8 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
9 The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer Unknown status NCT01845922 Phase 4
10 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4 Prasugrel
11 Treatment of the Dumping Syndrome With Lanreotide Autogel® Unknown status NCT00543179 Phase 4 Somatuline (Lanreotide Autogel®)
12 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
13 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
14 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
15 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
16 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
17 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
18 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
19 Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients Unknown status NCT01524510 Phase 4
20 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
21 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
22 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
23 LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients Unknown status NCT02077257 Phase 4 Rosuvastatin
24 Telmisartan Versus Ramipril After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
25 Efficacy Evaluation of Surfactant Administration Via Laryngeal Mask Airway Unknown status NCT01173237 Phase 4
26 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
27 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
28 Paradigm Shift in the Treatment of Patients With ACS Unknown status NCT02041650 Phase 4 Ticagrelor
29 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4 ticagrelor
30 The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
31 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
32 Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT01573715 Phase 4 NIMBEX;NIMBEX
33 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
34 Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ
35 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
36 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
37 Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS) Unknown status NCT02284503 Phase 4 Rosuvastatin
38 The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome Unknown status NCT01699126 Phase 4 Statin
39 Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI Unknown status NCT02201667 Phase 4 Ticagrelor;clopidogrel;Aspirin
40 Cost-utility Study of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01590420 Phase 4
41 Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
42 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
43 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes Unknown status NCT02126202 Phase 4
44 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
45 Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
46 Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome Unknown status NCT02037412 Phase 4 Ticagrelor;Clopidogrel
47 Rosuvastatin Effect on Telomere-telomerase System in ACS Unknown status NCT02299245 Phase 4 rosuvastatin
48 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
49 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
50 The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel Unknown status NCT01365221 Phase 4 Prasugrel;Prasugrel

Search NIH Clinical Center for Null Syndrome

Genetic Tests for Null Syndrome

Anatomical Context for Null Syndrome

MalaCards organs/tissues related to Null Syndrome:

39
Myeloid, T Cells, Lung, Bone, Heart, Bone Marrow, Ovary

Publications for Null Syndrome

Articles related to Null Syndrome:

id Title Authors Year
1
Molecular basis for Rh(null) syndrome: identification of three new missense mutations in the Rh50 glycoprotein gene. ( 10467273 )
1999
2
Anti-Rh 29 in a primigravida with rhesus null syndrome resulting in haemolytic disease of the newborn. ( 3120413 )
1987
3
Red cell membrane and cation deficiency in Rh null syndrome. ( 6324926 )
1984

Variations for Null Syndrome

Expression for Null Syndrome

Search GEO for disease gene expression data for Null Syndrome.

Pathways for Null Syndrome

GO Terms for Null Syndrome

Sources for Null Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....